IGHE and anaphylaxis: Omalizumab is a recombinant, humanized, monoclonal anti-IgE antibody that binds to circulating IgE molecules and prevents IgE binding to high- and low-affinity IgE receptors (FcεRI and FcεRII) on effector cells.[7] It is widely used for the treatment of severe asthma and refractory chronic urticaria.[7] In limited cases, omalizumab has been used to manage anaphylaxis.[8] We report a case of platelet-induced anaphylaxis that was successfully managed with omalizumab.